Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
Hafsah NabiOliver HendricksDorte Vendelbo JensenAnne Gitte LoftJens Kristian PedersenSøren Andreas JustKamilla DanebodHeidi Lausten MunkSalome KristensenNatalia ManiloAda ColicAsta LinauskasPia Høger ThygesenLouise Brot ChristensenMaren Høgberget KaliszNiels LomborgStavros ChrysidisJohnny Lillelund RaunMarlene AndersenFrank MehnertNiels Steen KroghMerete Lund HetlandBente GlintborgPublished in: RMD open (2022)
This real-world observational study of more than 1600 patients with inflammatory arthritis showed high 1-year retention following a nationwide infliximab biosimilar-to-biosimilar switch. Retention was higher in originator-experienced and in patients with low disease activity, suggesting outcomes to be affected by patient-related rather than drug-related factors.
Keyphrases
- rheumatoid arthritis
- disease activity
- end stage renal disease
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- oxidative stress
- newly diagnosed
- ejection fraction
- chronic kidney disease
- ulcerative colitis
- peritoneal dialysis
- prognostic factors
- juvenile idiopathic arthritis
- type diabetes
- emergency department
- metabolic syndrome
- patient reported outcomes
- adipose tissue
- skeletal muscle
- insulin resistance
- patient reported